Gilead’s new HIV drug shows lower side-effects over longer term

(Reuters) – Drugmaker Gilead Sciences Inc said data from a late-stage study showed that its experimental drug, Genvoya, showed reduced side-effects compared with an older version of the drug in treating HIV-infected patients over a longer term. The company said Genvoya was as good as Stribild, which is the older version, after 96 weeks of treatment and had lesser side-effects on patients’ kidneys and bones.
Sexual Health News Headlines – Yahoo! News